Safety and Efficacy of Khamira Gawzaban Sada (KGS) in Mild Cognitive Impairment: A Pilot Open-Label Clinical Trial
Acta Pharma Reports · 11.03.2022 · 1 (1) · 2-4
DOI: 10.51470/apr.2022.01.01.02 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Pharma Reports, online erschienen am 19.03.2022. Verfasst von Humaira Bano und 6 weiteren Autor:innen.
Abstract (Originalsprache)
Background
Mild cognitive impairment (MCI), termed Zu’f al-Dimagh in Unani medicine, is a clinically significant precursor to dementia with limited pharmacological options.
Objective
To evaluate the efficacy and safety of Khamira Gawzaban Sada (KGS), a standardized Pharmacopoeial Unani compound, in patients with MCI.
Methods
An open-label, single-arm pilot trial enrolled 100 participants (screened n=150) with MMSE scores of 10–23. KGS was administered orally at 10 g/day for six weeks. Primary outcome was change in MMSE score; secondary outcome was patient-reported Quality of Life (QoL). Safety was monitored through adverse event surveillance, laboratory parameters, and vital signs at baseline, Week 2, Week 4, and Week 6.
Results
Mean MMSE scores improved significantly from 16.2 (±2.8) at baseline to 22.4 (±1.9) at Week 6 (p
Zitieren
APA
Bano, H., Shaikh, N., Alam, S., Shah, A., Sheeraz, M., Ahmed, I., & Alam, M. M. (2022). Safety and Efficacy of Khamira Gawzaban Sada (KGS) in Mild Cognitive Impairment: A Pilot Open-Label Clinical Trial. Acta Pharma Reports, 1(1), 2-4. https://doi.org/10.51470/apr.2022.01.01.02
Vancouver
Bano H, Shaikh N, Alam S, Shah A, Sheeraz M, Ahmed I, et al. Safety and Efficacy of Khamira Gawzaban Sada (KGS) in Mild Cognitive Impairment: A Pilot Open-Label Clinical Trial. Acta Pharma Reports. 2022;1(1):2-4. doi:10.51470/apr.2022.01.01.02
BibTeX
@article{Bano2022,
author = {Bano, Humaira and Shaikh, Nikhat and Alam, Shah and Shah, Arjumand and Sheeraz, Mohammed and Ahmed, Irfan and Alam, MD Manzar},
title = {Safety and Efficacy of Khamira Gawzaban Sada (KGS) in Mild Cognitive Impairment: A Pilot Open-Label Clinical Trial},
journal = {Acta Pharma Reports},
year = {2022},
volume = {1},
number = {1},
pages = {2--4},
doi = {10.51470/apr.2022.01.01.02}
}
EUVIMED